A histone mutated tumor that is characterized by the presence of histone H3 K27M mutation located throughout the midline structures of the central nervous system.
Comprehensive, easy-to-understand information about this condition
How we create this content →The limited documentation surrounding diffuse midline glioma, H3 K27M-mutant, is primarily due to its rarity and the complexity of its clinical features. With fewer cases reported, systematic clinical studies have been challenging to conduct. Additionally, the genetic basis of this condition was only recently recognized, and ongoing research is needed to better understand its characteristics and treatment options.
To navigate your care effectively, seek out a neuro-oncologist with expertise in treating gliomas, particularly those with H3 K27M mutations. Additionally, consider reaching out to clinical trial centers that specialize in brain tumors, as they may offer access to cutting-edge treatments. You can find resources and information on clinical trials at ClinicalTrials.gov. While no specific patient organizations are currently identified for this condition, participating in clinical trials can provide valuable insights and support.
Currently, there is one orphan drug designated for this condition: dimethylaminomicheliolide Fumarate, which is still in development. There are also 21 active clinical trials focusing on various aspects of diffuse midline glioma, H3 K27M-mutant. For more information on these trials, you can visit ClinicalTrials.gov and search for the condition: https://clinicaltrials.gov/search?cond=diffuse%20midline%20glioma%2C%20H3%20K27M-mutant.
Actionable guidance for navigating care for diffuse midline glioma, H3 K27M-mutant
To navigate your care effectively, seek out a neuro-oncologist with expertise in treating gliomas, particularly those with H3 K27M mutations. Additionally, consider reaching out to clinical trial centers that specialize in brain tumors, as they may offer access to cutting-edge treatments. You can find resources and information on clinical trials at ClinicalTrials.gov. While no specific patient organizations are currently identified for this condition, participating in clinical trials can provide valuable insights and support.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The limited documentation surrounding diffuse midline glioma, H3 K27M-mutant, is primarily due to its rarity and the complexity of its clinical features. With fewer cases reported, systematic clinical studies have been challenging to conduct. Additionally, the genetic basis of this condition was only recently recognized, and ongoing research is needed to better understand its characteristics and treatment options.
To navigate your care effectively, seek out a neuro-oncologist with expertise in treating gliomas, particularly those with H3 K27M mutations. Additionally, consider reaching out to clinical trial centers that specialize in brain tumors, as they may offer access to cutting-edge treatments. You can find resources and information on clinical trials at ClinicalTrials.gov. While no specific patient organizations are currently identified for this condition, participating in clinical trials can provide valuable insights and support.
Currently, there is one orphan drug designated for this condition: dimethylaminomicheliolide Fumarate, which is still in development. There are also 21 active clinical trials focusing on various aspects of diffuse midline glioma, H3 K27M-mutant. For more information on these trials, you can visit ClinicalTrials.gov and search for the condition: https://clinicaltrials.gov/search?cond=diffuse%20midline%20glioma%2C%20H3%20K27M-mutant.
Actionable guidance for navigating care for diffuse midline glioma, H3 K27M-mutant
To navigate your care effectively, seek out a neuro-oncologist with expertise in treating gliomas, particularly those with H3 K27M mutations. Additionally, consider reaching out to clinical trial centers that specialize in brain tumors, as they may offer access to cutting-edge treatments. You can find resources and information on clinical trials at ClinicalTrials.gov. While no specific patient organizations are currently identified for this condition, participating in clinical trials can provide valuable insights and support.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The limited documentation surrounding diffuse midline glioma, H3 K27M-mutant, is primarily due to its rarity and the complexity of its clinical features. With fewer cases reported, systematic clinical studies have been challenging to conduct. Additionally, the genetic basis of this condition was only recently recognized, and ongoing research is needed to better understand its characteristics and treatment options.
To navigate your care effectively, seek out a neuro-oncologist with expertise in treating gliomas, particularly those with H3 K27M mutations. Additionally, consider reaching out to clinical trial centers that specialize in brain tumors, as they may offer access to cutting-edge treatments. You can find resources and information on clinical trials at ClinicalTrials.gov. While no specific patient organizations are currently identified for this condition, participating in clinical trials can provide valuable insights and support.
Currently, there is one orphan drug designated for this condition: dimethylaminomicheliolide Fumarate, which is still in development. There are also 21 active clinical trials focusing on various aspects of diffuse midline glioma, H3 K27M-mutant. For more information on these trials, you can visit ClinicalTrials.gov and search for the condition: https://clinicaltrials.gov/search?cond=diffuse%20midline%20glioma%2C%20H3%20K27M-mutant.
Actionable guidance for navigating care for diffuse midline glioma, H3 K27M-mutant
To navigate your care effectively, seek out a neuro-oncologist with expertise in treating gliomas, particularly those with H3 K27M mutations. Additionally, consider reaching out to clinical trial centers that specialize in brain tumors, as they may offer access to cutting-edge treatments. You can find resources and information on clinical trials at ClinicalTrials.gov. While no specific patient organizations are currently identified for this condition, participating in clinical trials can provide valuable insights and support.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
Consider asking your healthcare providers these condition-specific questions
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.